Supplemental Figure 1 Characterization of healthy donor-derived MSCs. The morphology of human MSCs (passage 5) was revealed by phase contrast microscopy (a). The adipogenic and osteogenic differentiation of the human MSCs were shown by oil red O staining (b) and Alizarin red S staining (c). Cell surface markers of human MSCs were detected by flow cytometry (d). Scale bar5200 mM. 
Supplemental Figure 5 The mechanisms of MSCs affect the IL-10 expression on CD8 1 CD28 2 T cells. The expression of IL-10 on CD8 1 CD28 2 T cells from healthy donors increased after the cocultured with MSCs. Neither inhibitors nor neutralization antibodies could reverse the expression of IL-10 (a, b). The gray histograms correspond to the isotype controls. Data are representative of three experiments. The bar graphs indicate the means6s.d. Statistically significant differences are indicated as follows: **P,0.01. 
Supplemental Figure 6 The mechanisms of MSCs affect the FasL expression on CD8 1 CD28 2 T cells. Supplemental Figure 7 MSCs inhibit CD8 1 CD28 2 T cells apoptosis. CD8 1 CD28 2 T cells and CD8 1 CD28 1 T cells were respectively cocultured with MSCs at a ratio of 5 : 1 (T cells : MSCs), and T cells were harvested at the indicated time points, then permeabilized and stained with propidium iodide to reveal hypodiploid peaks characteristic of apoptotic cells. MSCs significantly decreased the apoptosis of CD8 Pre-treatment Post-treatment P r e -t r e a t m e n t P o s t -t r e a t m e n t P r e -t r e a t m e n t P o s t -t r e a t m e n t P r e -t r e a t m e n t 
CD28
2 T cells were increased post-MSC treatment in CR/PR patients (n53) (c-f). The gray histograms correspond to the isotype controls. The bar graphs indicate the means6s.d., n510; statistically significant differences are indicated as follows: *P,0.05 and **P,0.01. Pre-treatment Post-treatment P r e -tr e a tm e n t P o s t-tr e a tm e n t Supplemental Figure 9 No change in the percentage of CD8 
Cellular & Molecular Immunology

